Document is current

Article History

Received: 17 June 2021

Accepted: 5 August 2021

First Online: 18 August 2021

Declarations

:

: The study received approval from MHS Institutional Review Board (IRB) committee at Bait Balev Hospital. Due to de-identified data extracting, informed consent was not requested by the IRB.

: Not applicable.

: MS, CMC and GC declare no conflict of interests. AR and IY declare consulting fees from Novo Nordisk and CuraLife. AK has received Grants and consulting fees from Astra Zeneca, Novonordisk and Boeheringer Ingelheim. MK has served on the advisory board/consultant for Amgen, Applied Therapeutics, Astra Zeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Janssen, Merck (Diabetes), Novo Nordisk, Sanofi, and Vifor Pharma; has received research grants from Astra Zeneca and Boehringer Ingelheim; has received other research support from Astra Zeneca. OM declares advisory board membership from AstraZeneca, Novo Nordisk, Eli Lilly, Sanofi, Merck Sharp & Dohme, Boehringer Ingelheim, BOL Pharma; Speaker’s bureau honorarium from AstraZeneca, Novo Nordisk, Eli Lilly, Sanofi, Merck Sharp & Dohme and Boehringer Ingelheim; and research grants from Novo Nordisk and AstraZeneca.